<DOC>
	<DOCNO>NCT00841698</DOCNO>
	<brief_summary>The objective study compare rate extent absorption paroxetine hydrochloride 40 mg film-coated tablet ( test ) versus Paxil® ( reference ) administer 1 x 40 mg film-coated tablet fast condition .</brief_summary>
	<brief_title>Paroxetine Hydrochloride 40 mg Tablets Under Fasting Conditions</brief_title>
	<detailed_description>Criteria Evaluation : FDA Bioequivalence Criteria Statistical Methods : FDA bioequivalence statistical method</detailed_description>
	<mesh_term>Paroxetine</mesh_term>
	<criteria>Inclusion Criteria Subjects females and/or male , nonsmoker , 18 year age old . Female Subjects postmenopausal surgically sterilize . Postmenopausal status define absence menses past 12 month , Sterile status define hysterectomy , bilateral oophorectomy tubal ligation least 6 month ago . Exclusion Criteria Subjects follow applies exclude study : Clinically significant illness within 4 week administration study medication . Clinically significant surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Subjects history renal , hepatic cardiovascular disease , tuberculosis , epilepsy , asthma , diabetes , psychosis glaucoma eligible study . History presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea , inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease condition know interfere absorption , distribution , metabolism excretion drug . Subjects history seizure . Subjects already episode mania . Any reason , opinion medical subinvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive urine drug screen screen . Positive test hepatitis B , hepatitis C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 ; heart rate le 50 bpm 100 bpm ) screening . Subjects BMI ≥30.0 . History significant alcohol abuse within six month screen visit indication regular use two unit alcohol per day ( 1 Unit = 150 mL wine 360 mL beer 45 mL alcohol 40 % ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month screen visit hard drug ( cocaine , phencyclidine ( PCP ) crack ) within 1 year screen visit . Any food allergy , intolerance , restriction special diet , opinion medical subinvestigator , contraindicate subject 's participation study . History allergic reaction paroxetine hydrochloride relate drug ( e.g . citalopram hydrobromide , fluoxetine hydrochloride , fluvoxamine maleate sertraline hydrochloride ) . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampin/rifabutin ; examples inhibitor : antidepressant , cimetidine , diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine , valproic acid , use investigational drug participation investigation study within 30 day prior administration study medication . Use prescription medication within 14 day prior administration study medication overthecounter product ) include natural product , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Subjects depot injection implant drug 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day . Donation loss whole blood prior administration study medication follow : Less 300 mL whole blood within 30 day 300 mL 500 mL whole blood within 45 day 500 mL whole blood within 56 day . Positive alcohol breath test screening . Subjects use tobacco form within 90 day precede study drug administration . Intolerance venipuncture . Additional exclusion criterion female subject : Breast feeding subject . Positive urine pregnancy test screening ( performed female ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>